Rationale Murine syngeneic tumor models have revealed efficacious systemic antitumor
responses following primary tumor in situ vaccination combined with targeted radionuclide …

Progress in animal radioimmunotherapy has been reviewed by highlighting 22 successful
experiments using human xenografts in rodent models. Significant tumor growth delay has …

Background/Aim: Previous work in rodent models showed that an autologous tissue vaccine
is both a safe and effective approach for treating cancer; however, as a translational step …

Canine malignant melanoma (MM) is a highly aggressive tumour with a low survival rate
and represents an ideal spontaneous model for the human counterpart. Considerable …

Background The antitumor effects of external beam radiation therapy (EBRT) are mediated,
in part, by an immune response. We have reported that a single fraction of 12 Gy EBRT …

The presence and benefit of a radiation therapy-associated immune reaction is of great
interest as the overall interest in cancer immunotherapy expands. The pathological …

In situ vaccination is an emerging cancer treatment strategy that uses local therapies to
stimulate a systemic antitumor immune response. We previously reported an in situ …

Multimodal treatment approaches, such as radio-immunotherapy, necessitate regimen
optimization and the investigation of the interactions of different modalities. The aim of this …

Interest in combining radiotherapy and immune checkpoint therapy is growing rapidly. In this
study, we explored a novel combination of this type to augment antitumor immune …

While rodent cancer models are essential for early proof-of-concept and mechanistic studies
for immune therapies, these models have limitations with regards to predicting the ultimate …